Comparative efficacy and safety of basal insulins: A review. Issue 6 (November 2021)

• Record Type: Journal Article
• Authors: Vargas-Uricoechea, Hernando; Aschner, Pablo
• Is Part Of: Diabetes & metabolic syndrome. Volume 15:Issue 6(2021)
• Publication Date: 2021-11
• Subjects: Diabetes -- Insulin -- Glargine -- Degludec; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2021.102318
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background and aim: To provide an update on the usefulness of basal insulin in patients with type 2 diabetes mellitus. Methods: We conducted a literature search using PubMed and MEDLINE, BIOSIS, Scopus, EMBASE, ClinicalTrials.gov, Google Scholar, and Springer Online Archives Collection until June 2021. Results: All basal insulins are similar in efficacy, with only small differences among them in terms of the risk of hypoglycemia. Conclusions: For type 2 diabetes mellitus, all basal insulins have a similar efficacy, with some advantage of Glar-300 and Deg-100 in reducing the risk of hypoglycemia compared to Glar-100. Highlights: Basal insulins all have a similar efficacy in metabolic control of type 2 diabetes mellitus. Insulin glargine-100 and detemir have a lower risk of hypoglycemia than NPH insulin. Insulin degludec-100 and glargine-300 have a lower risk of hypoglycemia than glargine-100. No important differences were found when comparing glargine-300 to degludec-100 and glargine-300 to degludec-200.